medigraphic.com
ISSN 2594-1526 (Electronic)
Antes Revista del Instituto Nacional de Enfermedades Respiratorias

 Ver anteriores al 2010

2021, Number 1

<< Back Next >>

Neumol Cir Torax 2021; 80 (1)

The use of tocilizumab in patients with COVID-19. Methodological and ethical considerations

Martínez-Michel O, Romero-Thirión II

Language: Spanish
References: 14
Page: 6-8
PDF size: 178.82 Kb.





REFERENCES

  1. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446. https://doi.org/10.3389/fimmu.2020.01446

  2. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473-474. https://doi.org/10.1126/science.abb8925

  3. Cortegiani A, Ippolito M, Greco M, Granone V, Protti A, Gregoretti C, et al. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. Pulmonology. 2021;27(1):52-66. https://doi.org/10.1016/j.pulmoe.2020.07.003

  4. Clinical Trial. Tocilizumab in COVID-19 pneumonia (TOCIVID-19). [Access date: 2021 January 6] Available from: https://www.clinicaltrials.gov/ct2/results?cond=covid-19&term=TOCILIZUMAB&cntry=&state=&city=&dist=

  5. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of tocilizumab in patients hospitalized with COVID-19. N Engl J Med. 2020;383(24):2333-2344. https://doi.org/10.1056/nejmoa2028836

  6. Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in nonventilated patients hospitalized with Covid-19 pneumonia. medRxiv [Internet]. 2020;(650):2020.10.21.20210203. Available from: https://doi.org/10.1101/2020.10.21.20210203

  7. Huang E, Jordan SC. Tocilizumab for Covid-19-The ongoing search for effective therapies. N Engl J Med. 2020;383(24):2387-2388. https://doi.org/10.1056/nejme2032071

  8. NIH. The COVID-19 Treatment Guidelines Panel's Statement on the Use of Tocilizumab for the Treatment of COVID-19. [Access date: 2021 January 6] Available from: https://www.covid19treatmentguidelines.nih.gov/immune-based-therapy/immunomodulators/

  9. REMAP-CAP Investigators, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021;1-12. doi: 10.1056/NEJMoa2100433.

  10. RECOVERY Collaborative Group, Horby PW, Pessoa-Amorim G, Peto L, Brightling CE, Sarkar R, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021.02.11.21249258; doi: https://doi.org/10.1101/2021.02.11.21249258.

  11. Vallejo RJ. Mito y realidad de la terapéutica electroconvulsiva. Med Clin Barcelona. 1983;(81):345-346.

  12. Savater F. "Cuidar al prójimo: compasión con pasión" ante el dolor reflexiones para afrontar la enfermedad y la muerte (Prólogo). Madrid: Temas de hoy; 2000. p. 13.

  13. Couceiro VA. Comités de ética y eutanasia. Madrid: Noesis; 1996. p. 293-312.

  14. Arent H. La condición humana. Barcelona: Paidós; 2005. p. 255-265.




2020     |     www.medigraphic.com